What is Suprax (cefexime), including its indications, dosing regimen, and contraindications?

Suprax (Cefixime): Overview, Indications, Dosing, and Contraindications

Suprax (cefixime) is a third-generation oral cephalosporin antibiotic with potent activity against H. influenzae but limited gram-positive coverage, including poor activity against S. pneumoniae and no activity against staphylococci or drug-resistant S. pneumoniae (DRSP). 1

What is Cefixime?

Cefixime is the prototype oral third-generation cephalosporin with a broad spectrum of antibacterial activity, particularly effective against many Enterobacteriaceae, H. influenzae, S. pyogenes, and B. catarrhalis 2. It is distinguished by its 3-hour elimination half-life, permitting once or twice daily dosing 2.

Spectrum of Activity

Key Strengths:

• Excellent activity against H. influenzae (including β-lactamase producing strains)
• Good coverage of gram-negative organisms
• Resistant to hydrolysis by many β-lactamases 2

Critical Limitations:

• Limited gram-positive coverage including S. pneumoniae 1
• No activity against staphylococci 1
• May fail against even penicillin-susceptible pneumococci 1
• No clinically significant activity against DRSP 1
• Inactive against Pseudomonas aeruginosa 2

Clinical Indications

Approved Uses:

Urinary Tract Infections:

• Acute uncomplicated UTIs in women 3, 4
• Demonstrated 98% clinical cure and bacteriologic eradication at 5-9 days post-therapy 4
• Particularly useful during pregnancy due to minimal fetal tissue penetration (<1% of dose) 3

Respiratory Tract Infections:

• Acute bacterial sinusitis 5
• Acute otitis media in children (8 mg/kg daily) 2
• Acute lower respiratory tract infections 2
• Exacerbations of chronic bronchitis 6

Upper Respiratory Infections:

• Acute tonsillitis or pharyngitis 2

Important Clinical Context:

Cefixime should NOT be used as first-line therapy for acute bacterial sinusitis or community-acquired pneumonia due to inadequate pneumococcal coverage 7. The 2005 sinusitis guidelines explicitly state that both cefixime and ceftibuten "have poor activity against S. pneumoniae and are especially ineffective against penicillin-resistant strains. Neither of these drugs should be used for acute bacterial sinusitis" 7.

Dosing Regimens

Adults:

• Standard dose: 400 mg once daily 3, 5, 4, 2
• Alternative: 200 mg twice daily 2
• Duration: Typically 7-10 days depending on indication 5, 6

Children:

• 8 mg/kg daily (as single dose or divided into 2 doses) 2
• Maximum daily dose should not exceed adult dosing

Special Populations:

Pregnancy:

• Safe for use during pregnancy 3
• Pharmacokinetic parameters remain stable during pregnancy 3
• Extremely low penetration into fetal tissues and breast milk 3

Renal Impairment:

• Dose adjustment required as cefixime is eliminated principally via renal excretion 1

Formulations

Dispersible Tablets (Cefixime EXPRESS, Suprax Solutab):

• Provide improved tolerability and adherence 3, 5
• Particularly beneficial for pregnant women due to ease of administration 3
• High oral bioavailability 3

Contraindications and Precautions

Absolute Contraindications:

• Known hypersensitivity to cefixime or other cephalosporins
• Severe allergic reactions to β-lactam antibiotics

Clinical Situations Where Cefixime Should Be Avoided:

1. Suspected or confirmed pneumococcal infections (including pneumonia, meningitis, severe sinusitis) 1, 7, 1
2. Staphylococcal infections (no activity) 1
3. Severe community-acquired respiratory infections where pneumococcal coverage is essential 7

Common Pitfalls:

Do not use cefixime when:

• Pneumococcal coverage is required
• Treating severe respiratory infections empirically
• Staphylococcal infection is suspected
• Patient has drug-resistant S. pneumoniae risk factors

Adverse Effects

Most Common:

• Diarrhea and stool changes (usually mild to moderate, transient) 2
• Typically occur in first few days of treatment 2

Frequency:

• Adverse reactions reported in approximately 6.7-10% of patients 5
• Generally well tolerated with favorable safety profile 5, 2

Clinical Efficacy

Demonstrated equivalence to:

• Co-trimoxazole for uncomplicated UTIs 4, 2
• Amoxicillin for acute lower respiratory tract infections 2
• Cefaclor for acute otitis media 2

Success rates:

• 91.7% therapeutic success in chronic bronchitis exacerbations 6
• 94.3% pathogen eradication rate 6
• 100% clinical cure in evaluable UTI patients at 5-9 days 4

Key Takeaway

Cefixime is best reserved for uncomplicated urinary tract infections and select respiratory infections where H. influenzae is the primary concern and pneumococcal coverage is not required. Its once-daily dosing and excellent safety profile make it particularly useful for outpatient UTI management, especially in pregnancy 3. However, its significant limitations in gram-positive coverage, particularly against S. pneumoniae and staphylococci, restrict its utility in empiric treatment of respiratory infections where these pathogens are common 1, 7, 1.